---
title: "Pfizer (NYSE:PFE) Price Target Cut to $24.00 by Analysts at UBS Group"
description: "UBS Group has lowered its price target for Pfizer (NYSE:PFE) from $28.00 to $24.00, maintaining a \"neutral\" rating. This adjustment suggests a potential upside of 10.37% from the previous close. Other"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/235300295.md"
published_at: "2025-04-09T22:02:19.000Z"
---

# Pfizer (NYSE:PFE) Price Target Cut to $24.00 by Analysts at UBS Group

> UBS Group has lowered its price target for Pfizer (NYSE:PFE) from $28.00 to $24.00, maintaining a "neutral" rating. This adjustment suggests a potential upside of 10.37% from the previous close. Other analysts have varied opinions, with some rating it as a "strong-buy" and others maintaining neutral or buy ratings. Pfizer's stock recently traded down 3.9% to $21.75, with an average target price of $31.07. The company reported strong quarterly earnings, exceeding expectations with a revenue of $17.76 billion.

Pfizer (NYSE:PFE - Get Free Report) had its price objective reduced by stock analysts at UBS Group from $28.00 to $24.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's price target points to a potential upside of 10.37% from the company's previous close.

-   2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

PFE has been the subject of several other research reports. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Bank of America reiterated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.07.

**Get Our Latest Analysis on PFE**

## Pfizer Trading Down 3.9 %

-   Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

Shares of NYSE:PFE traded down $0.89 during midday trading on Tuesday, reaching $21.75. 72,206,792 shares of the company's stock were exchanged, compared to its average volume of 47,080,777. The stock has a market cap of $123.33 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer has a fifty-two week low of $21.44 and a fifty-two week high of $31.54. The firm's 50 day simple moving average is $25.79 and its two-hundred day simple moving average is $26.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the business earned $0.10 earnings per share. The business's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

## Insider Activity at Pfizer

-   These Stocks Missed on Earnings, But Will Rebound Next Quarter

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

## Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC increased its position in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after acquiring an additional 2,923,537 shares during the period. Norges Bank purchased a new stake in Pfizer during the 4th quarter valued at approximately $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

## About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

## Featured Stories

-   Five stocks we like better than Pfizer
-   How Can Investors Benefit From After-Hours Trading
-   Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
-   What is the MACD Indicator and How to Use it in Your Trading
-   Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
-   The Role Economic Reports Play in a Successful Investment Strategy
-   Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 輝瑞在台灣開展新的 Elranatamab 研究，目標是收集現實世界的骨髓瘤數據 | 輝瑞公司（Pfizer Inc.，股票代碼：PFE）正在台灣啓動一項新的觀察性研究，以評估其多發性骨髓瘤藥物 elranatamab 在真實世界中的有效性。該研究旨在跟蹤患者的治療結果和治療模式，儘管尚未開始招募參與者。此舉預計將增強輝瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |
| 這位輝瑞分析師以看空的基調開始覆蓋；以下是週五的五大新啓動 | 華爾街頂級分析師已對多家公司啓動了覆蓋。Baird 的 David Koning 對 Affirm Holdings (AFRM) 給予中性評級，目標價為 55 美元。Piper Sandler 的 Biren Amin 對 OKYO Ph | [Link](https://longbridge.com/en/news/276467088.md) |
| 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) |
| 學習英偉達刺激芯片銷售，AMD 為 “AI 雲” 借款做擔保 | AMD 為擴大市場份額祭出金融 “狠招”！為初創公司 Crusoe 的 3 億美元購芯貸款提供擔保，承諾在其無客户時 “兜底” 租用芯片。這一復刻英偉達 “租卡雲” 路徑的策略雖能短期推高銷量，但也令 AMD 在 AI 需求放緩時面臨更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
